https://www.123articleonline.com/rss/author/281860/srishti-khuranaArticles written by Srishti Khurana from 123ArticleOnline.comen-usCopyright (c) 123ArticleOnline.com All rights reserved. https://www.123articleonline.com/articles/1187732/companion-diagnostics-development-services-market-2020-2030-report-features-an-extensive-study A detailed assessment of the current market landscape of companies offering companion diagnostics services, including information on the type of services offered, type of analytical technique used and regulatory certifications / accreditations, and other company-specific details (such as year of establishment, company size and geographical location). https://www.123articleonline.com/articles/1188659/currently-several-companies-claim-to-be-engaged-in-the-development-manufacturing-of-various-types In addition to enabling patients to self-medicate, these devices are designed to ensure safety during the dosing process and promote compliance to prescribed therapeutic regimens. Moreover, the adoption of autoinjectors, and other self-injection products, has enabled significant cost savings for end users by eliminating the need to visit hospitals / out-patient clinics for dosing. https://www.123articleonline.com/articles/1188859/given-the-increasing-number-of-licensing-deals-and-the-expected-approval-of-multiple-mid-late-stage Roots Analysis has done a detailed study on Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030, covering key aspects of the industry's evolution and identifying potential future growth opportunities. https://www.123articleonline.com/articles/1187745/more-than-35-industry-players-claim-to-offer-services-for-the-identification-characterization-and-d Drug discovery is challenging and involves several complexities. In order to continue to add new molecules their pipelines, drug developers are opting to outsource such operations to contract research organizations (CROs). Outsourcing of peptides and macrocycle drug discovery has emerged as one of the recent trends in the overall pharmaceutical domain. https://www.123articleonline.com/articles/1187893/more-than-40-large-volume-wearable-injectors-are-presently-available-under-development-for-the-adm The convenience of subcutaneous route of drug administration and the reformulation of intravenous drugs, reaching patent expiry, for SC delivery has provided an impetus to the development of large volume wearable injectors. In fact, according to the experts in this field, the industry is putting in significant efforts to develop efficient and effective drug-device combinations to deliver large volumes of drugs over a convenient period of time. https://www.123articleonline.com/articles/1188152/next-generation-contact-lenses-and-visual-prostheses-market-2019-2030 A detailed review of the landscape of novel ophthalmic products, highlighting the different categories of contact lenses and visual prostheses (bionic eye technologies) developed / being developed by various players across the world. It features information on the purpose of development (therapeutic, drug delivery, and diagnosis / monitoring), current development status, target indication(s), type of product, type of organization (industry or non-industry) and location of company headquarters. https://www.123articleonline.com/articles/1187731/over-180-companies-from-different-regions-across-the-globe-presently-claim-to-provide-services-for-t It is estimated that around 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise. On the other hand, there are numerous contract service providers, offering vast portfolios of services for diagnostic test / assay development. https://www.123articleonline.com/articles/1188167/over-270-companies-worldwide-have-the-necessary-expertise-to-offer-contract-manufacturing More than 100 medical devices were approved by the FDA in 2018, while several are currently being evaluated across more than 9,500 (active) clinical trials, worldwide. Further, increase in aging population, coupled with rise in the prevalence of chronic disorders, are likely to drive the demand for medical devices. Therefore, in order to reduce the overall cost and expedite the time to market, majority of original equipment manufacturers (OEMs) are outsourcing their medical device manufacturing operations to CMOs. https://www.123articleonline.com/articles/1188145/over-55-novel-ophthalmic-products-are-currently-available-being-developed-for-various-therapeutic Advancements in the domain of ophthalmology continue to expand the range of potential application areas for contact lenses. Presently, over 55 novel ophthalmic products have been developed or are being developed for the treatment of various ophthalmological disorders, diagnosis / monitoring of diseases and for restoring vision in the blind. The ongoing efforts to innovate in this domain are evident from the fact that more than 7,500 patents have been granted / filed since 2013. https://www.123articleonline.com/articles/1187883/presently-over-240-adc-therapy-candidates-are-being-evaluated-in-clinical-preclinical-stages-for With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects. https://www.123articleonline.com/articles/1187871/presently-there-are-more-than-10-approved-gene-therapies-over-465-product-candidates-are-being-eva Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMAÂ (AveXis) and ZYNTEGLO(TM) (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years. https://www.123articleonline.com/articles/1187763/several-players-are-currently-engaged-in-the-development-manufacturing-over-100-point-of-care-hand According to industry experts, handheld ultrasound imaging devices are being adopted at a faster pace by different end-users owing to their higher efficiency and wider applicability. Further, these devices have proven to be useful in quarantining patients demonstrating symptoms of pleural wall thickening and lung congestion, a characteristic of pneumonia, as well as observed in patients suffering from the novel coronavirus (COVID-19). https://www.123articleonline.com/articles/1187884/the-antibody-drug-conjugates-market-5th-edition-2019-2030-report-features-an-extensive-study A detailed assessment of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of linker, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target indication(s), line of treatment, route of administration and dosing frequency. https://www.123articleonline.com/articles/1188684/the-global-autoinjectors-market-3rd-edition-2020-2030-report-features-an-extensive-study-of-the An overview of the current market landscape of companies engaged in developing and / or manufacturing autoinjectors, providing information on the usability (disposable and reusable), type of primary drug container (cartridge, syringe and vial), volume of container, type of dose (fixed and variable), route of administration (intradermal, intramuscular and subcutaneous), actuation mechanism (automatic and manual) and feedback mechanism integrated in the device. It also provides details on the developers, highlighting their year of establishment, company size (small-sized, mid-sized and large), location of headquarters and location of manufacturing facilities https://www.123articleonline.com/articles/1187869/the-bispecific-antibody-therapeutics-market-4th-edition-2019-2030-report-features-an-extensive A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment. https://www.123articleonline.com/articles/1187874/the-gene-therapy-market-3rd-edition-2019-2030-report-features-an-extensive-study-of-the-current A detailed review of the overall landscape of gene therapies and genome editing therapies, including information on various drug / therapy developer companies, phase of development https://www.123articleonline.com/articles/1187895/the-large-volume-wearable-injectors-market-5th-edition-2020-2030-focus-on-bolus-basal-and-cont An overview of current market landscape of the large volume wearable injectors available for delivery of insulin and non-insulin drugs, providing information on status of development and device specifications https://www.123articleonline.com/articles/1187773/the-live-biotherapeutic-products-and-microbiome-contract-manufacturing-market-focus-on-active-phar A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics, including information on year of establishment, company size, scale of operation https://www.123articleonline.com/articles/1187748/the-peptides-and-macrocycle-drug-discovery-services-and-platforms-market-2020-2030-report-featur A detailed assessment of the current market landscape of companies offering peptide and macrocycle drug discovery services, including developer information (year of establishment, company size and location of headquarters), type of peptide manufactured (linear, cyclic, helical and others), drug discovery steps covered in service portfolio (target validation, hit identification, lead generation and lead optimization), peptide generation methods used (liquid phase synthesis, solid phase synthesis, microwave-assisted synthesis, recombinant methods and others), peptide modification services (C-terminal, N-terminal, fret / quenching tags, immunogenic conjugates, linkers / spacers, unnatural AAS, cyclization, stable isotope labels and post-translational modification services) and other services offered (peptide isolation / purification service, peptide detection / identification service and peptide quantification service). https://www.123articleonline.com/articles/1187877/the-antibody-drug-conjugates-market-is-estimated-to-be-worth-more-than-15-billion-in-2030-predicts Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatment; over the years, this upcoming class of targeted therapeutic agents has generated significant enthusiasm within the medical science community https://www.123articleonline.com/articles/1187879/the-antibody-drug-conjugates-market-is-projected-to-grow-at-an-annualized-rate-of-over-20-till-203 Roots Analysis has done a detailed report on Antibody Drug Conjugates Market, covering various important aspects of the industry and identifying key future growth opportunities. https://www.123articleonline.com/articles/1187862/the-bispecific-antibody-therapeutics-market-is-estimated-to-be-worth-usd-69-billion-in-2030-predic Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of 'two-target' artificially engineered drugs have generated significant enthusiasm within the medical science community https://www.123articleonline.com/articles/1187863/the-bispecific-antibody-therapeutics-market-is-projected-to-grow-at-an-annualized-rate-of-16-in-t Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry's evolution and identifying potential future growth opportunities. https://www.123articleonline.com/articles/1187723/the-companion-diagnostics-development-services-market-is-estimated-to-be-worth-over-usd-800-million In the last couple of years, a record number of personalized therapeutic products were approved in the US, establishing an urgent need for companion diagnostics and causing many drug developers to actively seek external support and expertise https://www.123articleonline.com/articles/1187726/the-companion-diagnostics-development-services-market-is-projected-to-grow-at-an-annualized-rate-of Roots Analysis has done a detailed report on Companion Diagnostics Development Services Market covering key aspects of the industry and identifying future growth opportunities https://www.123articleonline.com/articles/1187769/the-contract-manufacturing-market-for-live-biotherapeutics-and-microbiome-products-is-estimated-to-b Manufacturing live biotherapeutic product is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs. https://www.123articleonline.com/articles/1187870/the-gene-therapy-market-is-projected-to-grow-at-an-annualized-rate-of-45-till-2030 Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering key aspects of the industry's evolution and identifying potential future growth opportunities. https://www.123articleonline.com/articles/1188657/the-global-autoinjectors-market-is-projected-to-grow-at-an-annualized-rate-of-10-and-be-worth-arou Roots Analysis has done a detailed study on Global Autoinjectors Market (3rd Edition), 2020-2030, covering key aspects of the industry's evolution and identifying potential future growth opportunities. https://www.123articleonline.com/articles/1188656/the-global-autoinjectors-market-is-projected-to-grow-at-an-annualized-rate-of-over-10-till-2030 Autoinjectors have become an important part of modern healthcare, having demonstrated the potential to address a number of parenteral drug delivery related adverse events, and improve medication adherence among patients https://www.123articleonline.com/articles/1187752/the-global-handheld-ultrasound-imaging-devices-market-is-projected-to-be-over-usd-11-billion-by-203 Advances in the field of disease diagnostics have led to a substantial increase in the development of point-of-care medical imaging devices; handheld ultrasound scanners have emerged as a novel solution to cater to the unmet need in this domain. In fact, the demand for handheld ultrasound devices is on a surge amidst the COVID-19 pandemic. These portable, pocket-friendly, point-of-care devices have revolutionized the treatment of COVID-19 patients by provide remote access to doctors and ensures safety of the staff. https://www.123articleonline.com/articles/1187889/the-large-volume-wearable-injectors-market-is-estimated-to-be-worth-around-usd-600-million-by-2030 Large Volume Wearable Injectors have made it convenient to self-administer drugs in the home care setting, providing substantial cost benefits, improving medication adherence and reducing the risk of dosing errors, microbial contamination and needle-stick injuries; in fact, these drug delivery devices can prove to be potential vehicles for drug administration in disease outbreaks / pandemics (such as the one being faced due to the novel corona virus / COVID-19). https://www.123articleonline.com/articles/1187892/the-large-volume-wearable-injectors-market-is-projected-to-grow-at-an-annualized-rate-of-35-till Roots Analysis has done a detailed study on Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices, covering key aspects of the industry's current trends and identifying potential future growth opportunities. https://www.123articleonline.com/articles/1188157/the-medical-device-contract-manufacturing-market-is-estimated-to-be-worth-usd-126-billion-in-2030 Over the years outsourcing has become a popular trend among medical device developers, allowing such companies to leverage the expertise / substantial production capabilities of CMOs / CDMOs in order to gain cost and time related benefits https://www.123articleonline.com/articles/1188165/the-medical-device-contract-manufacturing-market-is-projected-to-grow-at-an-annualized-rate-of-8 Roots Analysis has done a detailed study on Medical Device Contract Manufacturing Market, 2019-2030, covering key aspects of the industry's evolution and identifying potential future growth opportunities. https://www.123articleonline.com/articles/1188686/the-medical-device-cro-market-is-estimated-to-be-worth-usd-157-billion-in-2030-predicts-roots-anal Advances in the medical device industry have led to a substantial increase in developmental complexity, clinical trial conduct, and stringency of regulatory review, causing sponsors to rely on the technical and regulatory affairs management expertise of CROs https://www.123articleonline.com/articles/1188694/the-medical-device-cro-market-is-projected-to-grow-at-an-annualized-rate-of-64-till-2030 Roots Analysis has done a detailed study on Medical Device CRO Market (2nd Edition), 2020-2030, covering various important aspects of the industry and identifying key future growth opportunities. https://www.123articleonline.com/articles/1187772/the-microbiome-therapies-pipeline-features-260-drugs-under-evaluation-across-different-phases-of-dev Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs. https://www.123articleonline.com/articles/1188140/the-next-generation-contact-lenses-and-visual-prostheses-market-is-estimated-to-be-worth-usd-37-bn Recent technological advances in the field of ophthalmology and the availability of new biomaterials have substantially expanded the range of potential application areas of contact lenses and enabled the development of novel prosthetic products https://www.123articleonline.com/articles/1188143/the-next-generation-contact-lenses-and-visual-prostheses-market-is-projected-to-grow Roots Analysis has done a detailed study on Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030, covering key aspects of the industry's evolution and identifying potential future growth opportunities. https://www.123articleonline.com/articles/1187743/the-next-generation-immune-checkpoint-inhibitors-and-stimulators-market-is-projected-to-grow-at-an-a Roots Analysis has done a detailed study on Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030, covering key aspects of the industry's evolution and identifying potential future growth opportunities. https://www.123articleonline.com/articles/1187742/the-peptides-and-macrocycle-drug-discovery-services-market-is-estimated-to-be-worth-usd-15-billion Given the recent developments in healthcare, supporting safety and efficacy of peptide and affiliated macrocycle drugs, the industry is presently witnessing an increase in discovery and development initiatives related to such therapeutic modalities. https://www.123articleonline.com/articles/1189639/to-sustain-future-growth-drug-developers-are-considering-such-devices-for-product-life-cycle-manage According to the Centers for Disease Control and Prevention, diabetes, migraine and cancer are responsible for 7 out of 10 deaths in the US. Further, as per the WHO, the prevalence of such chronic diseases is expected to reach 57% by 2020. https://www.123articleonline.com/articles/1187866/with-two-approved-drugs-and-close-to-300-clinical-preclinical-product-candidates-the-bispecific With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.